Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Files An 8-K Submission of Matters to a Vote of Security Holders

ME Staff 8-k
-
0
Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Files An 8-K Submission of Matters to a Vote of Security Holders

Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07

Adverum Biotechnologies, Inc. held its 2019 Annual Meeting of Stockholders on July 31, 2019. The following is a brief description of each matter voted upon at the Annual Meeting, as well as the final tally of the number of votes cast for, withheld or against each matter, and the number of abstentions and broker non-votes with respect to each matter.

Proposal No. 1. Election of Directors.

Adverum’s stockholders elected the Class II director nominees below to Adverum’s Board of Directors, each to hold office until the 2022 Annual Meeting of Stockholders and his or her successor is elected and has qualified, or until his or her earlier death, resignation or removal.

  37,740   36,572   —  


About Adverum Biotechnologies, Inc. (NASDAQ:ADVM)

Adverum Biotechnologies, Inc., formerly Avalanche Biotechnologies, Inc., is a gene therapy company. The Company is engaged in discovering and developing medicines to patients suffering from chronic or debilitating disease. The Company operates and manages its business in the segment of developing and commercializing gene therapeutics. It focuses on diseases with unmet medical need, including ophthalmic diseases, such as wet age-related macular degeneration (AMD), as well as rare genetic diseases. The Company’s product candidates include AVA-101 and AVA-201 for treatment of Wet AMD; AVA-322 and AVA-323 for the treatment of Color Vision Deficiency, and AVA-311 for the treatment of Juvenile X-linked Retinoschisis. It has generated human proof-of-concept data for AVA-101 in a Phase I trial with over eight wet AMD subjects conducted at Lions Eye Institute (LEI) in Australia. It is developing AVA-322 and AVA-323 for the treatment of color vision deficiency (CVD).